摘要
solriamfetol是选择性多巴胺-去甲肾上腺素再摄取抑制剂,于2019年3月被美国食品和药物管理局批准用于治疗阻塞性睡眠呼吸暂停和发作性睡病成年患者的白天过度睡眠。solriamfetol最常见的不良反应包括头痛、恶心、食欲下降、焦虑和失眠。
Solriamfetol, a selective dopamine-norepinephrine reuptake inhibitor, was approved by the U.S. Food and Drug Administration in March 2019 for the treatment of excessive daytime sleepiness in adult patients with obstructive sleep apnea and narcolepsy. The most common adverse reactions of solriamfetol are headache, nausea, anorexia, anxiety, and insomnia.
作者
万蒞
WAN Li(Department of Pharmacy,Hubei's Maternal and Child Health Hospital,Wuhan HUBEI 430070,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2020年第1期13-16,共4页
Chinese Journal of New Drugs and Clinical Remedies
